Search

Your search keyword '"Ianotto, Jean‐Christophe"' showing total 679 results

Search Constraints

Start Over You searched for: Author "Ianotto, Jean‐Christophe" Remove constraint Author: "Ianotto, Jean‐Christophe"
679 results on '"Ianotto, Jean‐Christophe"'

Search Results

151. Symptom Burden As Primary Driver for Therapy in Patients with Myelofibrosis: An Analysis By MPN International Quality of Life Study Group

152. Consideration of Symptom Burden Based Treatment in PV and ET Patients: An Analysis By MPN International Quality of Life Study Group

154. Efficacy and Safety of Erythropoietic-Stimulating Agents with Ruxolitinib in Myelofibrosis Patients : A Retrospective Analysis on 45 Patients. on Behalf of the French Intergroup of Myeloproliferative Disorders (FIM)

155. Thrombocytémie essentielle (TE) chez l’enfant et le jeune adulte

157. Symptomatic Profiles of Patients With Polycythemia Vera : Implications of Inadequately Controlled Disease

160. Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group

161. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B‐cell lymphoma

163. Symptomatic Profiles of Patients With Polycythemia Vera: Implications of Inadequately Controlled Disease

165. Unmet Needs for Symptom Control in Essential Thrombocythemia with Front Line Therapy

166. Addition of Lomustine (CCNU) to Induction and Post-Remission Chemotherapy for Fit Elderly AML Patients without Unfavorable Cytogenetics: Results of the Lamsa-2007 Goelams Trial

167. Sequential Analysis By Next Generation Sequencing of 18 Genes in Polycythemia Vera and Essential Thrombocythemia Reveals a Association Between Mutational Status and Clinical Outcome after 3-Year Follow-up

168. Impact of Disease Duration upon Symptom Burden Amongst Patients with Myeloproliferative Neoplasms (MPNs)

169. Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi-LMC)

170. Symptom Burden Profile in Myelofibrosis Patients with Thrombocytopenia: Lessons and Unmet Needs

171. Improved Survival by Adding Lomustine to Conventional Chemotherapy for Elderly Patients With AML Without Unfavorable Cytogenetics: Results of the LAM-SA 2007 FILO Trial.

172. Decreased turnover aspirin resistance by bidaily aspirin intake and efficient cytoreduction in myeloproliferative neoplasms.

173. Incidence and impact of atrial arrhythmias on thrombotic events in MPNs.

174. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.

176. CDKN2C Deletion on 1p32 Locus As Part of IrwazhScore, a New Risk Assessment Model for Venous Thromboembolism Occurring within 6-12 Months of Treatment Initiation in Newly Diagnosed Multiple Myeloma

177. Addition of Lomustine in the Treatment of Elderly Patients with Acute Myeloblastic Leukemia Improves Survival with Acceptably Increased Infectious Toxicity. a Filo Study

179. Long Term Outcome of Patients with MPN-Associated Myelofibrosis Treated with Peg-Interferon-α2a, a French Intergroup of Myeloproliferative Neoplasms (FIM) Study

180. Extinction of myeloproliferative neoplasm by acquisition of a lymphoid disease: JAK2 V617F and JAK2 exon 12 allele burden disappearance during the follow-up of two patients

181. Osteogenic Potential of Mesenchymal Stromal Cells Contributes to Primary Myelofibrosis

184. Transcriptome analysis of bone marrow mesenchymal stromal cells from patients with primary myelofibrosis

187. Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use : a Retrospective Evaluation of 1334 Patients

188. Impact of the Molecular Profile of Malignant Clones on the Response to Interferon Alpha (IFNa) Therapy in JAK2V617F-Negative Essential Thrombocythemia (ET)

190. Symptom Severity and Clinical Variables of Polycythemia Vera Patients with Splenomegaly, Phlebotomy Requirements and/or Hydroxyurea Use: a Retrospective Evaluation of 1334 Patients

191. Long Term Efficacy and Tolerance of Pegylated Interferon Alpha Therapy for Patients with High Risk Essential Thrombocythemia: An Observational Study of the French Intergroup of Myeloproliferative Disorders (FIM)

192. Differential Association of Calreticulin Type 1 and Type 2 Mutations with Myelofibrosis and Essential Thrombocytemia: Relevance for Disease Evolution

194. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.

195. Administration of direct oral anticoagulants in patients with myeloproliferative neoplasms.

196. JAK2V617F and calreticulin mutations in recurrent venous thromboembolism: results from the EDITH prospective cohort.

199. Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Catalog

Books, media, physical & digital resources